BofA/Merrill Lynch Downgrades Quest Diagnostics (DGX) to Underperform

February 23, 2015 6:29 AM

BofA/Merrill Lynch downgraded Quest Diagnostics (NYSE: DGX) from Neutral to Underperform with a price target of $68.00 (from $71.00).Analyst Robert ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found